Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review

References

• De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an International Expert Panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Gu R, Yang X, Wei H. Molecular landscape and targeted therapy of acute myeloid leukemia. Biomark Res. 2018;6:32.
   PubMed Web of Science ®Google Scholar
• Martignoles JA, Delhommeau F, Hirsch P. Genetic hierarchy of acute myeloid leukemia: from clonal hematopoiesis to molecular residual disease. Int J Mol Sci. 2018;19(12):3850.
   PubMed Web of Science ®Google Scholar
• Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53–61.
   PubMed Web of Science ®Google Scholar
• Bohl SR, Bullinger L, Rücker FG. New targeted agents in acute myeloid leukemia: new hope on the rise. Int J Mol Sci. 2019;20(8):1983.
   PubMed Web of Science ®Google Scholar
• Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606.
   PubMed Web of Science ®Google Scholar
• NCCN Practice Guidelines in Oncology: acute myeloid leukemia [Internet]. National Comprehensive Cancer Network; 2019; [cited 2019 Mar 26]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/aml_blocks.pdf
   Google Scholar
• Ferrara F, Barosi G, Venditti A, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27(5):997–999.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(6):721–749.
   PubMed Web of Science ®Google Scholar
• Brandwein JM, Zhu N, Kumar R, et al. Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines. Am J Blood Res. 2017;7(4):30–40.
   PubMed Web of Science ®Google Scholar
• Finn L, Dalovisio A, Foran J. Older patients with acute myeloid leukemia: treatment challenges and future directions. Ochsner J. 2017;17(4):398–404.
   PubMed Web of Science ®Google Scholar
• Sanford D, Ravandi F. Management of newly diagnosed acute myeloid leukemia in the elderly: current strategies and future directions. Drugs Aging. 2015;32(12):983–997.
   PubMed Web of Science ®Google Scholar
• Kantarjian H. Acute myeloid leukemia-major progress over four decades and glimpses into the future. Am J Hematol. 2016;91(1):131–145.
   PubMed Web of Science ®Google Scholar
• Pettit K, Odenike O. Defining and treating older adults with acute myeloid leukemia who are ineligible for intensive therapies. Front Oncol. 2015;5:280.
   PubMed Web of Science ®Google Scholar
• NCCN Practice Guidelines in Oncology: older adult oncology [Internet]. National Comprehensive Cancer Network; 2019; [cited 2019 Jun 25]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf
   Google Scholar
• Klepin HD, Estey E, Kadia T. More versus less therapy for older adults with acute myeloid leukemia: new perspectives on an old debate. Am Soc Clin Oncol Educ Book. 2019;39:421–432.
   PubMedGoogle Scholar
• Krug U, Rollig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376(9757):2000–2008.
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Satram-Hoang S, Hurst D, et al. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015;94(7):1127–1138.
   PubMed Web of Science ®Google Scholar
• Juliusson G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish acute leukemia registry. Clin Lymphoma Myeloma Leuk. 2011;11:S54–S59.
   PubMedGoogle Scholar
• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–4187.
   PubMed Web of Science ®Google Scholar
• Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–1924.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Storer BE, Elsawy M, et al. Intensive versus non-intensive induction therapy for patients (pts) with newly diagnosed acute myeloid leukemia (AML) using two different novel prognostic models. Blood. 2016;128(22):216.
   Web of Science ®Google Scholar
• Bell JA, Galaznik A, Farrelly E, et al. A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7 + 3 or a hypomethylating agent. Leuk Res. 2019;78:45–51.
   PubMed Web of Science ®Google Scholar
• Prebet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol. 2009;27(28):4747–4753.
   PubMed Web of Science ®Google Scholar
• Ross K, Gillespie-Twardy AL, Agha M, et al. Intensive chemotherapy in patients aged 70 years or older newly diagnosed with acute myeloid leukemia. Oncol Res. 2015;22(2):85–92.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422–4429.
   PubMed Web of Science ®Google Scholar
• Kim I, Koh Y, Yoon SS, et al. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients. Am J Hematol. 2013;88(1):10–15.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235–1248.
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information: Vidaza (azacitidine) [Internet]. US Food and Drug Administration; 2008; [cited 2019 Sep 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050794s011lbl.pdf
   Google Scholar
• Summary of product characteristics: Vidaza (azacitidine) [Internet]. European Medicines Agency; 2013; [cited 2019 Sep 12]. Available from: https://www.ema.europa.eu/en/documents/product-information/vidaza-epar-product-information_en.pdf
   Google Scholar
• Approval letter: cytarabine injection [Internet]. US Food and Drug Administration; 1999; [cited 2019 Sep 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/075383.PDF
   Google Scholar
• Highlights of prescribing information: Dacogen (decitabine) [Internet]. US Food and Drug Administration; 2018; [cited 2019 Sep 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021790s021lbl.pdf
   Google Scholar
• Summary of product characteristics: Dacogen (decitabine) [Internet]. European Medicines Agency; 2019; [cited 2019 Sep 12]. Available from: https://www.ema.europa.eu/en/documents/product-information/dacogen-epar-product-information_en.pdf
   Google Scholar
• Highlights of prescribing information: Daurismo (glasdegib) [Internet]. US Food and Drug Administration; 2020; [cited 2020 Mar 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210656s002s004lbl.pdf
   Google Scholar
• Summary of opinion (initial authorisation): Daurismo (glasdegib) [Internet]. European Medicines Agency; 2020; [cited 2020 May 06]. Available from: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-daurismo_en.pdf
   Google Scholar
• Highlights of prescribing information: Tibsovo (ivosidenib) [Internet]. US Food and Drug Administration; 2018; [cited 2019 Sep 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf
   Google Scholar
• Public summary of opinion on orphan designation: ivosidenib [Internet]. European Medicines Agency; 2017; [cited 2019 Mar 22]. Available from: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/16/1802-public-summary-opinion-orphan-designation-ivosidenib-treatment-acute-myeloid-leukaemia_en.pdf
   Google Scholar
• Highlights of prescribing information: Venclexta (venetoclax) [Internet]. US Food and Drug Administration; 2018 [cited 2019 Mar 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208573s009lbl.pdf
   Google Scholar
• Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379–389.
   PubMed Web of Science ®Google Scholar
• Wei AH, Strickland SA Jr., Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277–1284.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114–1124.
   PubMed Web of Science ®Google Scholar
• Amadori S, Suciu S, Selleslag D, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34(9):972–979.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Tallman MS, de Botton S, et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019;33(11):2575–2584.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299.
   PubMed Web of Science ®Google Scholar
• Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(6):697–712.
   Google Scholar
• Heuser M, Fiedler W, Sekeres MA, et al. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase 2 randomized trial. Clin Lymphoma Myeloma Leuk. 2019;19:S231.
   Web of Science ®Google Scholar
• Papayannidis C, Smith BD, Heuser M, et al. Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: long-term analysis of a phase 2 randomized trial. Clin Lymphoma Myeloma Leuk. 2019;19:S228–S229.
   PubMed Web of Science ®Google Scholar
• Cortes J, Heidel FH, Fiedler W, et al. Glasdegib improved overall survival in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who achieved complete remission (CR) and those who did not achieve CR. Poster session presented at: European Hematology Association; 2018 Jun 14–19; Stockholm, Sweden.
   Google Scholar
• Kwon Y, Bell TJ, Solem C, et al. Quality-adjusted survival for low-dose cytarabine (LDAC) versus glasdegib + LDAC among newly diagnosed acute myeloid leukemia patients who are not candidates for intensive chemotherapy: a Q-TWiST analysis. Blood. 2019;134(Suppl. 1):2610.
   Google Scholar
• Zeidan A, Schuster MW, Krauter J, et al. Clinical benefit of glasdegib in combination with azacitidine or low-dose cytarabine in patients with acute myeloid leukemia. Abstract at 62nd ASH Annual Meeting & Exposition; 2019 Dec 5–8; San Diego, CA.
   Google Scholar
• Sekeres MA, Schuster MW, Joris M, et al. A phase 1b study of glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. Abstract at 62nd ASH Annual Meeting & Exposition; 2019 Dec 5–8; San Diego, CA.
   Google Scholar
• AbbVie. AbbVie provides update from phase 3 study evaluating VENCLEXTA® (venetoclax) in combination with low-dose cytarabine in newly-diagnosed patients with acute myeloid leukemia (AML) [Internet]. AbbVie; 2020; [cited 2020 Mar 27]. Available from: https://news.abbvie.com/news/press-releases/abbvie-provides-update-from-phase-3-study-evaluating-venclexta-venetoclax-in-combination-with-low-dose-cytarabine-in-newly-diagnosed-patients-with-acute-myeloid-leukemia-aml.htm
   Google Scholar
• Bose P, Vachhani P, Cortes JE. Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat Options Oncol. 2017;18(3):17.
   PubMed Web of Science ®Google Scholar
• Papayannidis C, Sartor C, Marconi G, et al. Acute myeloid leukemia mutations: therapeutic implications. Int J Mol Sci. 2019;20(11):2721.
   Web of Science ®Google Scholar
• Highlights of prescribing information: Mylotarg (gemtuzumab ozogamicin) [Internet]. US Food and Drug Administration; 2017; [cited 2019 Mar 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf
   Google Scholar
• Summary of product characteristics: Mylotarg (gemtuzumab ozogamicin) [Internet]. European Medicines Agency; 2019; [cited 2019 Mar 22]. Available from: https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_en.pdf
   Google Scholar
• Highlights of prescribing information: Idhifa (enasidenib) [Internet]. US Food and Drug Administration; 2017; [cited 2019 Mar 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf
   Google Scholar
• Highlights of prescribing information: Xospata (gilteritinib) [Internet]. US Food and Drug Administration; 2018; [cited 2019 Mar 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf
   Google Scholar
• Campbell V, Copland M. Hedgehog signaling in cancer stem cells: a focus on hematological cancers. Stem Cells Cloning. 2015;8:27–38.
   PubMed Web of Science ®Google Scholar
• Ok CY, Singh RR, Vega F. Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. Am J Pathol. 2012;180(1):2–11.
   PubMed Web of Science ®Google Scholar
• Khan AA, Harrison CN, McLornan DP. Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase? Br J Haematol. 2015;170(3):323–335.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017;129(12):1627–1635.
   PubMed Web of Science ®Google Scholar
• Tauchi T, Okabe S, Katagiri S, et al. Targeting the Hedgehog signaling pathway by glasdegib limits the self-renewal of MDS-derived induced potent stem cells (iPSC). J Cancer Sci Ther. 2017;9(6):479–484.
   Google Scholar
• Fukushima N, Minami Y, Kakiuchi S, et al. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 2016;107(10):1422–1429.
   PubMed Web of Science ®Google Scholar
• AML-SCORE [Internet]. Study Alliance Leukemia; 2019; [cited 2019 Sep 13]. Available from: https://www.aml-score.org
   Google Scholar
• Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018;93(10):1267–1291.
   PubMed Web of Science ®Google Scholar
• Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29(33):4417–4423.
   PubMed Web of Science ®Google Scholar
• Walter RB, Othus M, Orlowski KF, et al. Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. Haematologica. 2018;103(3):e106–e109.
   PubMed Web of Science ®Google Scholar
• Larson RA. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol. 2007;20(1):29–37.
   PubMed Web of Science ®Google Scholar
• Granfeldt Ostgard LS, Medeiros BC, Sengelov H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33(31):3641–3649.
   PubMed Web of Science ®Google Scholar
• Boddu PC, Kantarjian HM, Ravandi F, et al. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017;123(16):3050–3060.
   PubMed Web of Science ®Google Scholar
• Boddu P, Kantarjian HM, Garcia-Manero G, et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017;1(17):1312–1323.
   PubMed Web of Science ®Google Scholar
• Shaik MN, LaBadie RR, Hee B, et al. Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib [abstract]. Clin Pharmacol Ther. 2020;107(Suppl. S1):S69.
   Google Scholar
• Lam JL, Vaz A, Hee B, et al. Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration. Xenobiotica. 2017;47(12):1064–1076.
   PubMed Web of Science ®Google Scholar
• Lin S, Shaik N, Martinelli G, et al. Population pharmacokinetics of glasdegib in patients with advanced hematologic malignancies and solid tumors. J Clin Pharmacol. 2019;60(5):605–616.
   Web of Science ®Google Scholar
• Masters JC, LaBadie RR, Salageanu J, et al. Pharmacokinetics (PK) and safety of glasdegib in participants with moderate and severe hepatic impairment: phase 1, open-label, single-dose, parallel-group study [abstract]. Clin Pharmacol Ther. 2020;107(Suppl. S1):S91.
   Google Scholar
• Lacouture ME, Dreno B, Ascierto PA, et al. Characterization and management of Hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21(10):1218–1229.
   PubMed Web of Science ®Google Scholar
• Yang X, Dinehart BA. Practical tips for managing Hedgehog pathway inhibitor side effects [Internet]. Practical Dermatology; 2017; [cited 2019 Sep 16]. Available from: http://v2.practicaldermatology.com/pdfs/pd0117_CF_BCC.pdf
   Google Scholar
• Mohan SV, Chang AL. Management of cutaneous and extracutaneous side effects of smoothened inhibitor therapy for advanced basal cell carcinoma. Clin Cancer Res. 2015;21(12):2677–2683.
   PubMed Web of Science ®Google Scholar
• Jacobsen AA, Kydd AR, Strasswimmer J. Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma. J Am Acad Dermatol. 2017;76(4):767–768.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Girmenia C, Bruggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221–3230.
   PubMed Web of Science ®Google Scholar
• Shaik MN, LaBadie RR, Rudin D, et al. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers. Cancer Chemother Pharmacol. 2014;74(2):411–418.
   PubMed Web of Science ®Google Scholar
• Shaik MN, Hee B, Wei H, et al. Evaluation of the effect of rifampin on the pharmacokinetics of the smoothened inhibitor glasdegib in healthy volunteers. Br J Clin Pharmacol. 2018;84(6):1346–1353.
   PubMed Web of Science ®Google Scholar
• Giri N, Lam LH, LaBadie RR, et al. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers. Cancer Chemother Pharmacol. 2017;80(6):1249–1260.
   PubMed Web of Science ®Google Scholar
• Shaik N, Hee B, Wei H, et al. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study. Cancer Chemother Pharmacol. 2019;83(3):463–472.
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics: Odomzo (sonidegib) [Internet]. European Medicines Agency; 2018; [cited 2019 Mar 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/odomzo-epar-product-information_en.pdf
   Google Scholar
• Summary of product characteristics: Erivedge (vismodegib) [Internet]. European Medicines Agency; 2019; [cited 2019 Mar 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/erivedge-epar-product-information_en.pdf
   Google Scholar
• Highlights of prescribing information: Erivedge [Internet]. US Food and Drug Administration; 2012; [cited 2019 Mar 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf
   Google Scholar
• Highlights of prescribing information: Odomzo [Internet]. US Food and Drug Administration; 2016; [cited 2019 Mar 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205266s002lbl.pdf
   Google Scholar
• Basset-Seguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334–348.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Gutzmer R, Kieran MW, et al. Hedgehog signaling inhibitors in solid and hematological cancers. Cancer Treat Rev. 2019;76:41–50.
   PubMed Web of Science ®Google Scholar
• Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(Suppl. 5):v111–v118.
   PubMed Web of Science ®Google Scholar